Aviano

• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 Non small cell lung cancer (NSCLC)
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide … Recruiting
  2023-503795-24-00 7 2022-09-16 Avanced Non-Small Cell Lung Cancer
• Study of STK-012 Alone and with Other Treatments in Patients with Advanced Lung Cancer and Other Cancers Recruiting
  2025-522632-14-00 4 2026-05-11 Non-small cell lung cancer (NSCLC)
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma Recruiting
  2025-524542-10-00 4 2026-04-14 Endometrial cancer
• ROMANCE Recruiting
  2025-521319-38-00 4 2026-03-11 metastatic colorectal cancer
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting
  2025-521904-23-00 4 2026-02-17 Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study. Recruiting
  2023-509180-24-00 4 2026-02-12 vulvar cancer
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part … Recruiting
  2025-522151-26-00 5 2026-02-06 Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS … Recruiting
  2024-519798-20-00 4 2026-01-15 pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
• Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcom … Recruiting
  2024-518167-35-01 4 2025-12-19 Patients with Metastatic Osteosarcoma
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting
  2025-521003-52-00 9 2025-12-19 HER2 Expressing Advanced Breast Cancer
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced … Recruiting
  2024-519871-24-00 10 2025-11-11 Breast cancer
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel

Showing 49–72 of 210 trials